Related Research Articles
Prostate cancer is cancer of the prostate. The prostate is a gland in the male reproductive system that surrounds the urethra just below the bladder. Most prostate cancers are slow growing. Cancerous cells may spread to other areas of the body, particularly the bones and lymph nodes. It may initially cause no symptoms. In later stages, symptoms include pain or difficulty urinating, blood in the urine, or pain in the pelvis or back. Benign prostatic hyperplasia may produce similar symptoms. Other late symptoms include fatigue, due to low levels of red blood cells.
Metastasis is a pathogenic agent's spread from an initial or primary site to a different or secondary site within the host's body; the term is typically used when referring to metastasis by a cancerous tumor. The newly pathological sites, then, are metastases (mets). It is generally distinguished from cancer invasion, which is the direct extension and penetration by cancer cells into neighboring tissues.
The University of Technology Sydney (UTS) is a public research university located in Sydney, Australia. Although its origins are said to trace back to the 1870s, the university was founded in its current form in 1988. As of 2020, UTS enrols 46,328 students through its 9 faculties and schools.
Children's Medical Research Institute (CMRI) is an Australian-based independent medical research institute located in Westmead, Sydney NSW that conducts research into children's genetic diseases. As of 2019, current research is focused on cancer, birth defects, neurological conditions such as epilepsy, and gene therapy to treat genetic diseases. CMRI created and continues to operate Australia's Jeans for Genes fundraising campaign.
Richard G. Pestell is an Australian oncologist and endocrinologist who is Distinguished Professor, Translational Medical Research, and the President of the Pennsylvania Cancer and Regenerative Medicine Research Center at the Baruch S. Blumberg Institute. He was previously Executive Vice President of Thomas Jefferson University and Director of the Sidney Kimmel Cancer Center of Thomas Jefferson University. Pestell was appointed an Officer of the Order of Australia in the 2019 Queen's Birthday Honours for distinguished service to medicine and medical education.
Dendreon is a biotechnology company. Its lead product, Provenge, is an immunotherapy for prostate cancer. It consists of a mixture of the patient's own blood cells that have been incubated with the Dendreon PAP-GM-CSF fusion protein. Phase III clinical trial results demonstrating a survival benefit for prostate cancer patients receiving the drug were presented at the AUA meeting on April 28, 2009. After going through the approval process, Provenge was given full approval by the FDA on April 29, 2010. Dendreon's stock value fell 66% on August 4, 2011, after abandoning its forecast for its debut drug Provenge.
Shahrokh François Shariat is currently professor and chairman of the department of urology, Medical University of Vienna, Vienna General Hospital, Vienna, Austria. He is also adjunct professor of urology at Weill Cornell Medical Center, New York, NY; adjunct professor of urology at the University of Texas Southwestern Medical Center, Dallas, TX, USA; adjunct professor of urology at the Faculty of Medicine, Charles University, Prague, CZ; adjunct professor of urology at I.M. Sechenov First Moscow State Medical University, Moscow, RU; honorary professor of urology, University of Jordan, Amman, JO; and doctor honoris causa, Carol Davila University of Medicine and Pharmacy, Bucharest, RO. He has published more than 1400 peer-reviewed research papers, more than 500 non-peer-reviewed papers, and 26 book chapters. He has been voted as the most influential urologist in 2020 and also the most cited PCa researcher in the German speaking area.
Professor Minesh P Mehta, MD, FASTRO, is an American radiation oncologist and physician-scientist of Indian origin, Ugandan birth, Zambian Schooling and American Training, who contributed to the field of oncology for more than two and half decades.
Miltenyi Biotec is a global biotechnology company headquartered near Cologne in Bergisch Gladbach, Germany. The company is a provider of products and services that support scientists, clinical researchers, and physicians across basic research, translational research, and clinical applications. The company offers solutions covering techniques of sample preparation, cell separation, cell sorting, flow cytometry, cell culture, molecular analysis, clinical applications and small animal imaging. Miltenyi Biotec has more than 3,000 employees in 28 countries and more than 17,000 products.
Pamela J. Russell was an Australian academic researcher of immunology, bladder and prostate research. Russell was awarded Membership of the Order of Australia (AM) for her research on prostate and bladder cancer in 2003.
Professor Colleen Nelson is a scientist in prostate cancer research. Professor Nelson founded and directs the Australian Prostate Cancer Research Centre - Queensland (APCRC-Q). The Centre, based at the Translational Research Institute and the Princess Alexandra Hospital, spans the spectrum of discovery of new therapeutic targets and their preclinical and clinical development. Professor Nelson is also Chair of Prostate Cancer Research at Queensland University of Technology (QUT).
Michelle Haber is an Australian cancer researcher.
Judith Ann Clements is an Australian academic and educator, specializing in Kallikrein proteases in prostate and ovarian cancers. Clements is the Scientific Director at the Australian Prostate Cancer Research Centre – Queensland and was head of the Cancer Research Program at the Institute of Health and Biomedical Innovation (IHBI) of Queensland University of Technology at the Translational Research Institute (Australia) from 1997–2014.
Health Translation Queensland is the first Advanced Health Research Translation Centre in Queensland, Australia. The organisation’s purpose is to strengthen the linkages between healthcare, research and education in order to deliver better health outcomes for the community. By encouraging and supporting collaboration, BDHP assists the translation and integration of cutting-edge research and innovation into healthcare delivery.
Hudson Institute of Medical Research is an independent, not-for-profit medical research institute, based in the Melbourne suburb of Clayton in Victoria.
Carl H. June is an American immunologist and oncologist. He is currently the Richard W. Vague Professor in Immunotherapy in the Department of Pathology and Laboratory Medicine at the Perelman School of Medicine of the University of Pennsylvania. He is most well known for his research into T cell therapies for the treatment of cancer. In 2020 he was elected to the American Philosophical Society.
Maria Kavallaris is an Australian scientist, based at the University of New South Wales' Children's Cancer Institute, where she is best known for her contributions to the field of cancer research. On 25 January 2019, Kavallaris was appointed a member of the Order of Australia.
Marguerite Virginia Evans-Galea is the co-founder and CEO of Women in STEMM Australia. STEMM. Her research is focused on gene therapy and neurodegenerative diseases.
Suzanne Kathleen Chambers, is a Professor and Dean of the Faculty of Health at Sydney's University of Technology. She specialises in psycho-oncology, and has received Queen's Birthday honours. Chambers has worked on psycho-oncology, prostate cancer, health economics and psychological interventions including the distress and adjustments after cancer.
References
- 1 2 "Rose Martiniello-Wilks | University of Technology Sydney, Sydney". Uts.edu.au. 2014-08-05. Retrieved 2014-08-18.
- 1 2 "New cancer hope | UTS News Room". Newsroom.uts.edu.au. Retrieved 2014-08-18.
- ↑ "Dr Rosetta Martiniello-Wilks — Australian-Canadian Prostate Cancer Research Alliance". Aus-canprostatealliance.org. 2010-07-30. Retrieved 2014-08-18.
- ↑ http://www.agts.org.au/docs/committee/Bio_RosettaMartiniello-Wilks.pdf [ bare URL PDF ]